The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and...

Area of Science:

• Clinical trial design
• Pharmaceutical development
• Biostatistics

Background:

• Clinical development frequently encounters "false-negatives," where effective treatments are incorrectly identified as ineffective.
• Statistical errors, particularly "false-negatives," are more prevalent in underpowered early-phase trials, leading to premature termination of promising therapies.
• Limited data is available on these eliminated treatments, hindering further investigation and potential therapeutic advancements.

Purpose of the Study:

• To simulate the economic impact of early-phase statistical power on drug development productivity.
• To compare the effects of increased statistical power versus increased alpha stringency in phase II trials.
• To evaluate the cost-effectiveness of enhancing early-phase trial power.

Main Methods:

• Economic productivity simulations were conducted across three developmental scenarios.
• Scenario 1 represented the status quo (50% power phase II, 90% power phase III).
• Scenario 2 incorporated increased phase II power (80%), and Scenario 3 used increased alpha stringency (1%) at phase II.

Main Results:

• Increasing phase II statistical power to 80% (Scenario 2) resulted in an average 60.4% increase in productivity and a 52.4% increase in profit.
• Scenario 3, with increased alpha stringency, demonstrated no significant advantages over the status quo.
• The additional costs associated with higher phase II power were offset by substantial gains in productivity.

Conclusions:

• Enhancing statistical power in phase II clinical trials is a cost-effective strategy to improve drug development productivity.
• Increased power in early phases minimizes "false-negatives," allowing more effective treatments to advance.
• The study recommends increasing phase II power as a corrective measure to optimize resource allocation and therapeutic success rates.